FibroBiologics (FBLG) vs GT Biopharma (GTBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
FibroBiologics is the larger company by market cap ($6.3 million vs $6.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBLG | GTBP |
|---|---|---|
| Share price | $0.705 | $2.96 |
| Market cap | $6.34M | $6.33M |
| 1-day change | -15.06% | -6.92% |
| YTD return | — | +277.07% |
| 1-year return | — | +303.27% |
| 5-year return | — | -97.77% |
| EPS (TTM) | $-2.51 | $-128.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-18.65M | $-28.35M |
| 52-week high | $9.60 | $23.60 |
| 52-week low | $0.62 | $2.87 |
| Distance from 52-week high | -92.66% | -87.46% |
| Analyst consensus | none | none |
| Avg. price target upside | +1673.05% | +2433.78% |
| Average volume | 160.05K | 78.16K |
| Shares outstanding | 8.99M | 2.14M |
| Employees | 15 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About FibroBiologics
FBLG stock →FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About GT Biopharma
GTBP stock →GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
FBLG vs GTBP FAQ
Which is bigger, FibroBiologics or GT Biopharma?
FibroBiologics (FBLG) is larger, with a market capitalization of $6.34M compared with $6.33M for GT Biopharma (GTBP).
Are FibroBiologics and GT Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.